Valkit.ai lands global lab tech customer, replacing legacy validation tool

Valkit.ai says a global analytical and clinical laboratory technology company with about $6.95 billion in annual revenue has chosen its platform for validation work across internal and external users. The win marks a second recent displacement of the same legacy Gen 1 tool as life sciences companies shift to broader, faster digital validation systems.

Why it matters: - The deal adds another large life sciences customer for Valkit.ai in a market where validation tools must serve both internal quality teams and external regulated customers. - The company being replaced was a Gen 1 digital validation platform that was not built for that dual-audience use case. - The win signals demand for platforms that can move validation evidence across organizational and customer boundaries without adding seat-based costs.

What happened: - A global leader in analytical and clinical laboratory technologies selected Valkit.ai as its digital validation platform of record. - The customer has about $6.95 billion in annual revenue and roughly 18,000 employees worldwide. - Valkit.ai said the deployment replaces an incumbent Gen 1 validation tool. - The announcement came on July 27, 2026, and refers to a second recent displacement of the same legacy platform.

The details: - Valkit.ai will support full Computer System Validation lifecycle management from User Requirements Specification through Validation Summary Report. - The platform’s global cloning capability distributes complete validation packages across organizational boundaries in seconds. - The licensing model uses fixed project pricing with no named seats. - Internal teams, vendors, contractors and external reviewers can use the platform at no incremental cost. - The platform includes AI-assisted documentation with mandatory human review and e-signature. - Valkit.ai includes native 21 CFR Part 11 and EU Annex 11 controls. - The platform offers automated traceability and true-copy PDF export into any receiving eQMS. - Valkit.ai says customer data is isolated and is never used to train third-party large language models. - The company’s validation footprint covers internal GxP systems and the qualification evidence required by its customers.

Between the lines: - The customer choice points to a shift away from tools built mainly to manage documents inside one company’s walls. - Validation vendors are being judged on whether they can support both compliance control and fast evidence sharing. - The repeated loss of the same legacy platform suggests buyers may be consolidating around newer architectures rather than patching old ones.

What's next: - Valkit.ai will roll out as the customer’s validation platform of record. - The company will use the platform across CSV activities and external evidence sharing. - Valkit.ai is likely to keep pitching the same architecture and pricing model to other regulated life sciences companies.

The bottom line: - Valkit.ai is turning a legacy-tool replacement into a broader message: validation platforms now have to serve enterprise compliance and customer-facing qualification at the same time.